Using Genomic Information to Guide Ibrutinib Treatment Decisions in Chronic Lymphocytic Leukaemia: A Cost-Effectiveness Analysis
James Buchanan,
Sarah Wordsworth,
Ruth Clifford,
Pauline Robbe,
Jenny C. Taylor,
Anna Schuh and
Samantha J. L. Knight
Additional contact information
Sarah Wordsworth: Nuffield Department of Population Health, University of Oxford
Ruth Clifford: Oxford University Hospitals Trust
Pauline Robbe: Oxford University Hospitals Trust
Jenny C. Taylor: National Institute for Health Research Oxford Biomedical Research Centre
Anna Schuh: Oxford University Hospitals Trust
Samantha J. L. Knight: National Institute for Health Research Oxford Biomedical Research Centre
PharmacoEconomics, 2017, vol. 35, issue 8, No 9, 845-858
Abstract:
Abstract Background Genomic tests may improve the stratification of patients to receive new therapies in several disease areas. However, the use of expensive targeted therapies can impact on the cost effectiveness of these tests. This study presents an economic evaluation of genomic testing in chronic lymphocytic leukaemia in the context of the UK National Health Service. Methods Cost-effectiveness and cost-utility analyses (using life-years and quality-adjusted life-years) were undertaken from a National Health Service and societal perspective. Five strategies were evaluated across several age groups using Markov modelling: three strategies that reflected varying current genetic testing practice and two configurations of genomic testing (including ibrutinib treatment). Results Genomic testing strategies yielded the most life-years/quality-adjusted life-years per patient, but were not cost effective compared with a threshold of £30,000 per life-year/quality-adjusted life-year gained. Cost-effectiveness acceptability curves indicated that there was some uncertainty surrounding this result. A genomic testing strategy becomes the most cost-effective option if a higher end-of-life cost-effectiveness threshold of £50,000 is applied, if a societal costing perspective is considered in 25-year-old patients or if the cost of ibrutinib treatment falls. Conclusion Stratifying patients with chronic lymphocytic leukaemia to targeted treatment using genomic testing improves health outcomes, but will likely only represent a cost-effective use of limited National Health Service resources if a higher cost-effectiveness threshold or societal costing perspective is applied, or if the price of ibrutinib treatment is reduced. This result may be broadly indicative of the likely cost effectiveness of other genomic tests that inform the stratification of patients to high cost-targeted therapies.
Date: 2017
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (1)
Downloads: (external link)
http://link.springer.com/10.1007/s40273-017-0519-z Abstract (text/html)
Access to the full text of the articles in this series is restricted.
Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.
Export reference: BibTeX
RIS (EndNote, ProCite, RefMan)
HTML/Text
Persistent link: https://EconPapers.repec.org/RePEc:spr:pharme:v:35:y:2017:i:8:d:10.1007_s40273-017-0519-z
Ordering information: This journal article can be ordered from
http://www.springer.com/economics/journal/40273
DOI: 10.1007/s40273-017-0519-z
Access Statistics for this article
PharmacoEconomics is currently edited by Timothy Wrightson and Christopher I. Carswell
More articles in PharmacoEconomics from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().